TRIAL OF BRYOSTATIN 1 GIVEN AS CONTINUOUS INFUSION IN CANCER PATIENTS

对癌症患者持续输注苔藓抑素 1 的试验

• 批准号: 6297540
• 负责人: Ross C Donehower
• 金额: $ 0.23万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297540
• 关键词: bioassay; bryostatin; clinical research; clinical trials; drug administration rate /duration; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; pharmacokinetics

This protocol is to determine the safety and toxicity of bryostatin 1 given as a brief or continuous infusion in cancer patients every 21 days, to evaluate the pharmacokinetcic parameters of byrostatin 1 in this patient population. As no assay exists for this drug, several bioassays will be evaluated in this study. The study is looking for preliminary evidence of therapeutic activity of pharmacokinetic assay of bryostatin 1 activity.

本方案旨在确定苔藓抑素 1 的安全性和毒性 癌症患者每 21 次进行一次短暂或连续输注 天，评估Byrostatin 1的药代动力学参数 这个患者群体。 由于尚无针对该药物的检测方法，因此有几种 本研究将评估生物测定。 该研究正在寻找 药代动力学测定治疗活性的初步证据 苔藓抑素 1 活性。